BDSX

Biodesix (BDSX)

About Biodesix (BDSX)

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Details

Daily high
$8.43
Daily low
$7.50
Price at open
$7.75
52 Week High
$32.20
52 Week Low
$3.44
Market cap
63.6M
Dividend yield
0.00%
Volume
81,029
Avg. volume
315,264
P/E ratio
-1.49

Biodesix News

Details

Daily high
$8.43
Daily low
$7.50
Price at open
$7.75
52 Week High
$32.20
52 Week Low
$3.44
Market cap
63.6M
Dividend yield
0.00%
Volume
81,029
Avg. volume
315,264
P/E ratio
-1.49